NVNO Quote, Financials, Valuation and Earnings

NeuroOne Medical Technologies has a net margin of -- compared to enVVeno Medical's net margin of 54.53%. enVVeno Medical's return on equity of -- beat NeuroOne Medical Technologies's return on equity of -238.93%.

enVVeno Medical has a consensus price target of $16.50, signalling upside risk potential of 634.97%. On the other hand NeuroOne Medical Technologies has an analysts' consensus of -- which suggests that it could grow by 262.19%. Given that enVVeno Medical has higher upside potential than NeuroOne Medical Technologies, analysts believe enVVeno Medical is more attractive than NeuroOne Medical Technologies.

enVVeno Medical has a beta of 1.040, which suggesting that the stock is 3.991% more volatile than S&P 500. In comparison NeuroOne Medical Technologies has a beta of 0.692, suggesting its less volatile than the S&P 500 by 30.823%.

enVVeno Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NeuroOne Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. enVVeno Medical pays -- of its earnings as a dividend. NeuroOne Medical Technologies pays out -- of its earnings as a dividend.

enVVeno Medical quarterly revenues are --, which are smaller than NeuroOne Medical Technologies quarterly revenues of $3.3M. enVVeno Medical's net income of -$6.2M is lower than NeuroOne Medical Technologies's net income of $1.8M. Notably, enVVeno Medical's price-to-earnings ratio is -- while NeuroOne Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for enVVeno Medical is 206.10x versus 2.74x for NeuroOne Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Nutriband has a net margin of -- compared to enVVeno Medical's net margin of -211%. enVVeno Medical's return on equity of -- beat Nutriband's return on equity of -69.58%.

enVVeno Medical has a consensus price target of $16.50, signalling upside risk potential of 634.97%. On the other hand Nutriband has an analysts' consensus of $13.00 which suggests that it could grow by 162.1%. Given that enVVeno Medical has higher upside potential than Nutriband, analysts believe enVVeno Medical is more attractive than Nutriband.

enVVeno Medical has a beta of 1.040, which suggesting that the stock is 3.991% more volatile than S&P 500. In comparison Nutriband has a beta of 1.049, suggesting its more volatile than the S&P 500 by 4.944%.

enVVeno Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nutriband offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. enVVeno Medical pays -- of its earnings as a dividend. Nutriband pays out -- of its earnings as a dividend.

enVVeno Medical quarterly revenues are --, which are smaller than Nutriband quarterly revenues of $645.8K. enVVeno Medical's net income of -$6.2M is lower than Nutriband's net income of -$1.4M. Notably, enVVeno Medical's price-to-earnings ratio is -- while Nutriband's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for enVVeno Medical is 206.10x versus 24.31x for Nutriband. Usually stocks with elevated PS ratios are considered overvalued.

Pulse Biosciences has a net margin of -- compared to enVVeno Medical's net margin of --. enVVeno Medical's return on equity of -- beat Pulse Biosciences's return on equity of --.

enVVeno Medical has a consensus price target of $16.50, signalling upside risk potential of 634.97%. On the other hand Pulse Biosciences has an analysts' consensus of -- which suggests that it could fall by -69.77%. Given that enVVeno Medical has higher upside potential than Pulse Biosciences, analysts believe enVVeno Medical is more attractive than Pulse Biosciences.

enVVeno Medical has a beta of 1.040, which suggesting that the stock is 3.991% more volatile than S&P 500. In comparison Pulse Biosciences has a beta of 1.874, suggesting its more volatile than the S&P 500 by 87.435%.

enVVeno Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pulse Biosciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. enVVeno Medical pays -- of its earnings as a dividend. Pulse Biosciences pays out -- of its earnings as a dividend.

enVVeno Medical quarterly revenues are --, which are smaller than Pulse Biosciences quarterly revenues of --. enVVeno Medical's net income of -$6.2M is higher than Pulse Biosciences's net income of -$10.1M. Notably, enVVeno Medical's price-to-earnings ratio is -- while Pulse Biosciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for enVVeno Medical is 206.10x versus -- for Pulse Biosciences. Usually stocks with elevated PS ratios are considered overvalued.

SINTX Technologies has a net margin of -- compared to enVVeno Medical's net margin of -882.81%. enVVeno Medical's return on equity of -- beat SINTX Technologies's return on equity of -148.9%.

enVVeno Medical has a consensus price target of $16.50, signalling upside risk potential of 634.97%. On the other hand SINTX Technologies has an analysts' consensus of $300.00 which suggests that it could grow by 3683.78%. Given that SINTX Technologies has higher upside potential than enVVeno Medical, analysts believe SINTX Technologies is more attractive than enVVeno Medical.

enVVeno Medical has a beta of 1.040, which suggesting that the stock is 3.991% more volatile than S&P 500. In comparison SINTX Technologies has a beta of 1.124, suggesting its more volatile than the S&P 500 by 12.355%.

enVVeno Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SINTX Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. enVVeno Medical pays -- of its earnings as a dividend. SINTX Technologies pays out -- of its earnings as a dividend.

enVVeno Medical quarterly revenues are --, which are smaller than SINTX Technologies quarterly revenues of $192K. enVVeno Medical's net income of -$6.2M is lower than SINTX Technologies's net income of -$1.7M. Notably, enVVeno Medical's price-to-earnings ratio is -- while SINTX Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for enVVeno Medical is 206.10x versus 1.15x for SINTX Technologies. Usually stocks with elevated PS ratios are considered overvalued.